Rioja-Blanco, Elisa
Arroyo-Solera, Irene
Álamo, Patricia
Casanova, Isolda
Gallardo, Alberto
Unzueta, Ugutz
Serna, Naroa
Sánchez-García, Laura
Quer, Miquel
Villaverde, Antonio
Vázquez, Esther
León, Xavier
Alba-Castellón, Lorena
Mangues, Ramon
Funding for this research was provided by:
Instituto de Salud Carlos III (PI21/00150, PI18/ 00650, PIE15/00028, PI15/00378, PI19/01661, PI17/00584, CP19/00028)
Agencia Estatal de Investigación (BIO2016-76063-R, AEI/FEDER, UE, PID2019-105416RB-I00/AEI/10.13039/501100011033)
Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CB06/01/ 1031, 4NanoMets, VENOM4CANCER, NANOREMOTE, NANOSCAPE)
Agència de Gestió d’Ajuts Universitaris i de Recerca (2017- SGR-865, 2017SGR-229, 2020FI_B2 00168, 2018FI_B2_00051)
Fundación Josep Carreras Contra la Leucemia (P/AG)
Fundación Científica Asociación Española Contra el Cáncer
Generalitat de Catalunya (PERIS SLT006/17/00093)
Article History
Received: 23 September 2021
Accepted: 19 January 2022
First Online: 4 February 2022
Declarations
:
: HNSCC patient samples were obtained in accordance with the Hospital de la Santa Creu i Sant Pau Institutional Review Board. Written informed consent was acquired from all the patients involved in this study. All animal experiments were approved by the Hospital de la Santa Creu i Sant Pau Animal Ethics Committee.
: Not applicable.
: Antonio Villaverde, Esther Vázquez, Ugutz Unzueta, Ramon Mangues, and Isolda Casanova are cited as inventors in PCT/EP2012/050513 covering Targeted delivery of therapeutic molecules to CXCR4 cells, and in PCT/EP2018/061732, covering Therapeutic Nanostructured Proteins. All other authors report no conflicts of interest in this work.